Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 125

1.

Effective In Vivo Topical Delivery of siRNA and Gene Silencing in Intact Corneal Epithelium Using a Modified Cell-Penetrating Peptide.

Schiroli D, Gómara MJ, Maurizi E, Atkinson SD, Mairs L, Christie KA, Cobice DF, McCrudden CM, Nesbit MA, Haro I, Moore T.

Mol Ther Nucleic Acids. 2019 Sep 6;17:891-906. doi: 10.1016/j.omtn.2019.07.017. Epub 2019 Aug 1.

2.

Rheumatoid Arthritis Initiating as Palindromic Rheumatism: A Distinct Clinical Phenotype?

Castellanos-Moreira R, Rodriguez-Garcia SC, Gómez-Puerta JA, Ruiz-Esquide V, Camacho O, Ramírez J, Cuervo A, Morlá R, Cañete JD, Haro I, Sanmarti R.

J Rheumatol. 2019 Aug 1. pii: jrheum.190061. doi: 10.3899/jrheum.190061. [Epub ahead of print]

PMID:
31371648
3.

Development of a multiplex assay based on chimeric citrullinated peptides as proof of concept for diagnosis of rheumatoid arthritis.

García-Moreno C, Gómara MJ, Bleda MJ, Sanmartí R, Haro I.

PLoS One. 2019 May 2;14(5):e0215927. doi: 10.1371/journal.pone.0215927. eCollection 2019.

4.

Peptide Assembly on the Membrane Determines the HIV-1 Inhibitory Activity of Dual-Targeting Fusion Inhibitor Peptides.

Gomara MJ, Perez Y, Martinez JP, Barnadas-Rodriguez R, Schultz A, von Briesen H, Peralvarez-Marin A, Meyerhans A, Haro I.

Sci Rep. 2019 Mar 1;9(1):3257. doi: 10.1038/s41598-019-40125-4.

5.

Guiding the humoral response against HIV-1 toward a MPER adjacent region by immunization with a VLP-formulated antibody-selected envelope variant.

Beltran-Pavez C, Ferreira CB, Merino-Mansilla A, Fabra-Garcia A, Casadella M, Noguera-Julian M, Paredes R, Olvera A, Haro I, Brander C, Garcia F, Gatell JM, Yuste E, Sanchez-Merino V.

PLoS One. 2018 Dec 19;13(12):e0208345. doi: 10.1371/journal.pone.0208345. eCollection 2018.

6.

Design, Characterization, and Biopharmaceutical Behavior of Nanoparticles Loaded with an HIV-1 Fusion Inhibitor Peptide.

Ariza-Sáenz M, Espina M, Calpena A, Gómara MJ, Pérez-Pomeda I, Haro I, García ML.

Mol Pharm. 2018 Nov 5;15(11):5005-5018. doi: 10.1021/acs.molpharmaceut.8b00609. Epub 2018 Oct 3.

7.

Bilateral hydrosalpinx in patients with Hirschsprung's disease.

Palazón P, Saura L, de Haro I, Martín-Solé O, Albert A, Tarrado X, Julià V.

J Pediatr Surg. 2018 Oct;53(10):1945-1950. doi: 10.1016/j.jpedsurg.2018.01.011. Epub 2018 Jan 31.

PMID:
29467083
8.

Comparative study of the diagnostic and prognostic value of antibodies against chimeric citrullinated synthetic peptides and CCP3/CCP3.1 assays.

Gómara MJ, Rodríguez J, Bleda MJ, Salvador JP, Sanmartí R, Haro I.

Clin Chem Lab Med. 2018 Jan 26;56(2):285-293. doi: 10.1515/cclm-2017-0264.

PMID:
28850543
9.

Penetration of polymeric nanoparticles loaded with an HIV-1 inhibitor peptide derived from GB virus C in a vaginal mucosa model.

Ariza-Sáenz M, Espina M, Bolaños N, Calpena AC, Gomara MJ, Haro I, García ML.

Eur J Pharm Biopharm. 2017 Nov;120:98-106. doi: 10.1016/j.ejpb.2017.08.008. Epub 2017 Aug 24.

10.

Structural Study of a New HIV-1 Entry Inhibitor and Interaction with the HIV-1 Fusion Peptide in Dodecylphosphocholine Micelles.

Pérez Y, Gómara MJ, Yuste E, Gómez-Gutierrez P, Pérez JJ, Haro I.

Chemistry. 2017 Aug 25;23(48):11703-11713. doi: 10.1002/chem.201702531. Epub 2017 Aug 3.

PMID:
28677862
11.

Differing specificities and isotypes of anti-citrullinated peptide/protein antibodies in palindromic rheumatism and rheumatoid arthritis.

Cabrera-Villalba S, Gomara MJ, Cañete JD, Ramírez J, Salvador G, Ruiz-Esquide V, Hernández MV, Inciarte-Mundo J, Haro I, Sanmartí R.

Arthritis Res Ther. 2017 Jun 15;19(1):141. doi: 10.1186/s13075-017-1329-6.

12.

Anal canal duplication and triplication: a rare entity with different presentations.

Palazon P, Julia V, Saura L, de Haro I, Bejarano M, Rovira C, Tarrado X.

Pediatr Surg Int. 2017 May;33(5):609-617. doi: 10.1007/s00383-017-4074-7. Epub 2017 Mar 2.

PMID:
28255623
13.

Feeding dynamics, consumption rates and daily ration of wahoo Acanthocybium solandri in Indo-Pacific waters.

Perelman JN, Schmidt KN, Haro I, Tibbetts IR, Zischke MT.

J Fish Biol. 2017 May;90(5):1842-1860. doi: 10.1111/jfb.13270. Epub 2017 Feb 19.

PMID:
28217894
14.

Lipid raft-like liposomes used for targeted delivery of a chimeric entry-inhibitor peptide with anti-HIV-1 activity.

Gómara MJ, Pérez-Pomeda I, Gatell JM, Sánchez-Merino V, Yuste E, Haro I.

Nanomedicine. 2017 Feb;13(2):601-609. doi: 10.1016/j.nano.2016.08.023. Epub 2016 Aug 24.

PMID:
27565689
15.

Routine delayed voiding cystourethography after initial successful endoscopic treatment with Dextranomer/Hialuronic Acid Copolimer (Dx/HA) of vesicoureteral reflux (VUR). Is it necessary?

García-Aparicio L, Blázquez-Gómez E, Vila Santandreu A, Camacho Diaz JA, Vila-Cots J, Ramos Cebrian M, de Haro I, Martin O, Tarrado X.

Actas Urol Esp. 2016 Dec;40(10):635-639. doi: 10.1016/j.acuro.2016.02.007. Epub 2016 May 6. English, Spanish.

PMID:
27161091
16.

Definition of an 18-mer Synthetic Peptide Derived from the GB virus C E1 Protein as a New HIV-1 Entry Inhibitor.

Gómara MJ, Sánchez-Merino V, Paús A, Merino-Mansilla A, Gatell JM, Yuste E, Haro I.

Biochim Biophys Acta. 2016 Jun;1860(6):1139-48. doi: 10.1016/j.bbagen.2016.02.008. Epub 2016 Feb 22.

PMID:
26905802
17.

Miscibility and Langmuir Studies of the Interaction of E2 (279-298) Peptide Sequence of Hepatitis G Virus/GB Virus-C with Dipalmitoylphosphatidyl Choline and Dimiristoylphosphatidyl Choline Phospholipids.

Miñones J Jr, Muñoz M, Miñones Trillo J, Haro I, Busquets MA, Alsina MA.

Langmuir. 2015 Sep 22;31(37):10161-72. doi: 10.1021/acs.langmuir.5b00712. Epub 2015 Sep 8.

PMID:
26161460
18.

Postoperative vesicoureteral reflux after high-pressure balloon dilation of the ureterovesical junction in primary obstructive megaureter. Incidence, management and predisposing factors.

García-Aparicio L, Blázquez-Gómez E, de Haro I, Garcia-Smith N, Bejarano M, Martin O, Rodo J.

World J Urol. 2015 Dec;33(12):2103-6. doi: 10.1007/s00345-015-1565-9. Epub 2015 Apr 22.

PMID:
25899625
19.

Conjugation of cell-penetrating peptides with poly(lactic-co-glycolic acid)-polyethylene glycol nanoparticles improves ocular drug delivery.

Vasconcelos A, Vega E, Pérez Y, Gómara MJ, García ML, Haro I.

Int J Nanomedicine. 2015 Jan 27;10:609-31. doi: 10.2147/IJN.S71198. eCollection 2015.

20.

The use of citrullinated peptides for the diagnosis and prognosis of rheumatoid arthritis.

Haro I, Gómara MJ.

Curr Top Med Chem. 2014;14(23):2729-33.

PMID:
25515746
21.

IL-18 is not therapeutic for neovascular age-related macular degeneration.

Hirano Y, Yasuma T, Mizutani T, Fowler BJ, Tarallo V, Yasuma R, Kim Y, Bastos-Carvalho A, Kerur N, Gelfand BD, Bogdanovich S, He S, Zhang X, Nozaki M, Ijima R, Kaneko H, Ogura Y, Terasaki H, Nagai H, Haro I, Núñez G, Ambati BK, Hinton DR, Ambati J.

Nat Med. 2014 Dec;20(12):1372-5. doi: 10.1038/nm.3671. No abstract available.

22.

Surface behavior of peptides from E1 GBV-C protein: Interaction with anionic model membranes and importance in HIV-1 FP inhibition.

Galatola R, Cruz A, Gómara MJ, Prat J, Alsina MA, Haro I, Pujol M.

Biochim Biophys Acta. 2015 Feb;1848(2):392-407. doi: 10.1016/j.bbamem.2014.10.033. Epub 2014 Oct 30.

23.

A cyclic GB virus C derived peptide with anti-HIV-1 activity targets the fusion peptide of HIV-1.

Galatola R, Vasconcelos A, Pérez Y, Cruz A, Pujol M, Alsina MA, Gómara MJ, Haro I.

Eur J Med Chem. 2014 Oct 30;86:589-604. doi: 10.1016/j.ejmech.2014.09.020. Epub 2014 Sep 8.

PMID:
25218908
24.

Bacterial characteristics and clinical significance of ureteral double-J stents in children.

García-Aparicio L, Blázquez-Gómez E, Martin O, Krauel L, de Haro I, Rodó J.

Actas Urol Esp. 2015 Jan-Feb;39(1):53-6. doi: 10.1016/j.acuro.2014.04.008. Epub 2014 Jun 18. English, Spanish.

PMID:
24954842
25.

Modification of FP-HIV activity by peptide sequences of GB virus C: a biophysical approach.

Domènech O, Ortiz A, Pujol M, Haro I, Muñoz M, Alsina MA, Prat J, Busquets MA, Girona V.

Biochim Biophys Acta. 2014 May;1838(5):1274-80. doi: 10.1016/j.bbamem.2014.02.001. Epub 2014 Feb 11.

26.

Differences in synovial fluid cytokine levels but not in synovial tissue cell infiltrate between anti-citrullinated peptide/protein antibody-positive and -negative rheumatoid arthritis patients.

Gómez-Puerta JA, Celis R, Hernández MV, Ruiz-Esquide V, Ramírez J, Haro I, Cañete JD, Sanmartí R.

Arthritis Res Ther. 2013 Nov 7;15(6):R182. doi: 10.1186/ar4372.

27.

HIV-1 inhibiting capacity of novel forms of presentation of GB virus C peptide domains is enhanced by coordination to gold compounds.

Gómara MJ, Galatola R, Gutiérrez A, Gimeno MC, Gatell JM, Sánchez-Merino V, Yuste E, Haro I.

Curr Med Chem. 2014;21(2):238-50. Review.

PMID:
24083612
28.

Updating the use of synthetic peptides as inhibitors of HIV-1 entry.

Gómara MJ, Haro I.

Curr Med Chem. 2014 Apr;21(10):1188-200. Review.

PMID:
23931277
29.

Use of high-pressure balloon dilatation of the ureterovesical junction instead of ureteral reimplantation to treat primary obstructive megaureter: is it justified?

García-Aparicio L, Blázquez-Gómez E, Martin O, Palazón P, Manzanares A, García-Smith N, Bejarano M, de Haro I, Ribó JM.

J Pediatr Urol. 2013 Dec;9(6 Pt B):1229-33. doi: 10.1016/j.jpurol.2013.05.019. Epub 2013 Jun 21.

PMID:
23796389
30.

Contribution of the Tyr-1 in Plantaricin149a to disrupt phospholipid model membranes.

Lopes JL, Gómara MJ, Haro I, Tonarelli G, Beltramini LM.

Int J Mol Sci. 2013 Jun 7;14(6):12313-28. doi: 10.3390/ijms140612313.

31.

Citrullinated peptides in the diagnosis of rheumatoid arthritis.

Gómara MJ, Haro I.

Curr Top Med Chem. 2013;13(6):743-51. Review.

PMID:
23574523
32.

Rheumatoid arthritis: current advances in pathogenesis, diagnosis and therapy.

Haro I, Sanmartí R.

Curr Top Med Chem. 2013;13(6):697. No abstract available.

PMID:
23574517
33.

Acute and delayed vesicoureteral obstruction after endoscopic treatment of primary vesicoureteral reflux with dextranomer/hyaluronic acid copolymer: why and how to manage.

García-Aparicio L, Rodo J, Palazon P, Martín O, Blázquez-Gómez E, Manzanares A, García-Smith N, Bejarano M, de Haro I, Ribó JM.

J Pediatr Urol. 2013 Aug;9(4):493-7. doi: 10.1016/j.jpurol.2013.02.007. Epub 2013 Mar 16.

PMID:
23507288
34.

Interaction of two overlapped synthetic peptides from GB virus C with charged mono and bilayers.

Alay M, Haro I, Alsina MA, Girona V, Prat J, Busquets MA.

Colloids Surf B Biointerfaces. 2013 May 1;105:7-13. doi: 10.1016/j.colsurfb.2012.11.026. Epub 2013 Jan 6.

PMID:
23352943
35.

Design and application of GB virus C (GBV-C) peptide microarrays for diagnosis of GBV-C/HIV-1 co-infection.

Fernández L, Bleda MJ, Gómara MJ, Haro I.

Anal Bioanal Chem. 2013 May;405(12):3973-82. doi: 10.1007/s00216-012-6585-3. Epub 2012 Dec 13.

PMID:
23232955
36.

Oligonucleotide-peptide conjugates: solid-phase synthesis under acidic conditions and use in ELISA assays.

Aviñó A, Gómara MJ, Malakoutikhah M, Haro I, Eritja R.

Molecules. 2012 Nov 22;17(12):13825-43. doi: 10.3390/molecules171213825.

37.

Physicochemical characterization of GBV-C E1 peptides as potential inhibitors of HIV-1 fusion peptide: interaction with model membranes.

Sánchez-Martín MJ, Cruz A, Busquets MA, Haro I, Alsina MA, Pujol M.

Int J Pharm. 2012 Oct 15;436(1-2):593-601. doi: 10.1016/j.ijpharm.2012.07.051. Epub 2012 Jul 31.

PMID:
22868231
38.

Anti-citrullinated peptide antibodies in the serum of heavy smokers without rheumatoid arthritis. A differential effect of chronic obstructive pulmonary disease?

Ruiz-Esquide V, Gómara MJ, Peinado VI, Gómez Puerta JA, Barberá JA, Cañete Jde D, Haro I, Sanmartí R.

Clin Rheumatol. 2012 Jul;31(7):1047-50. doi: 10.1007/s10067-012-1971-y. Epub 2012 Mar 31.

PMID:
22466712
39.

Synthetic peptides derived from an N-terminal domain of the E2 protein of GB virus C in the study of GBV-C/HIV-1 co-infection.

Fernández L, Chan WC, Egido M, Gómara MJ, Haro I.

J Pept Sci. 2012 May;18(5):326-35. doi: 10.1002/psc.2403. Epub 2012 Mar 22.

PMID:
22438139
40.

Effects of smoking on disease activity and radiographic progression in early rheumatoid arthritis.

Ruiz-Esquide V, Gómez-Puerta JA, Cañete JD, Graell E, Vazquez I, Ercilla MG, Viñas O, Gómez-Centeno A, Haro I, Sanmartí R.

J Rheumatol. 2011 Dec;38(12):2536-9. doi: 10.3899/jrheum.110410. Epub 2011 Nov 1.

PMID:
22045838
41.

The use of chimeric vimentin citrullinated peptides for the diagnosis of rheumatoid arthritis.

Malakoutikhah M, Gómara MJ, Gómez-Puerta JA, Sanmartí R, Haro I.

J Med Chem. 2011 Nov 10;54(21):7486-92. doi: 10.1021/jm200563u. Epub 2011 Oct 7.

PMID:
21981664
42.

Biophysical investigations of GBV-C E1 peptides as potential inhibitors of HIV-1 fusion peptide.

Sánchez-Martín MJ, Urbán P, Pujol M, Haro I, Alsina MA, Busquets MA.

Chemphyschem. 2011 Oct 24;12(15):2816-22. doi: 10.1002/cphc.201100407. Epub 2011 Sep 8.

PMID:
21905195
43.

Carbon nanotube composite peptide-based biosensors as putative diagnostic tools for rheumatoid arthritis.

Villa Mde G, Jiménez-Jorquera C, Haro I, Gomara MJ, Sanmartí R, Fernández-Sánchez C, Mendoza E.

Biosens Bioelectron. 2011 Sep 15;27(1):113-8. doi: 10.1016/j.bios.2011.06.026. Epub 2011 Jun 28.

PMID:
21764288
44.

Effect of E1(64-81) hepatitis G peptide on the in vitro interaction of HIV-1 fusion peptide with membrane models.

Sánchez-Martín MJ, Busquets MA, Girona V, Haro I, Alsina MA, Pujol M.

Biochim Biophys Acta. 2011 Sep;1808(9):2178-88. doi: 10.1016/j.bbamem.2011.05.020. Epub 2011 Jun 7.

45.

Diagnostic value of anti-GBV-C antibodies in HIV-infected patients.

Gómara MJ, Fernández L, Pérez T, Tenckhoff S, Casanovas A, Tillmann HL, Haro I.

Chem Biol Drug Des. 2011 Aug;78(2):277-82. doi: 10.1111/j.1747-0285.2011.01143.x. Epub 2011 Jun 20.

PMID:
21599855
46.

Analysis of HIV-1 fusion peptide inhibition by synthetic peptides from E1 protein of GB virus C.

Sánchez-Martín MJ, Hristova K, Pujol M, Gómara MJ, Haro I, Alsina MA, Busquets MA.

J Colloid Interface Sci. 2011 Aug 1;360(1):124-31. doi: 10.1016/j.jcis.2011.04.053. Epub 2011 Apr 24.

PMID:
21565353
47.

Study of the inhibition capacity of an 18-mer peptide domain of GBV-C virus on gp41-FP HIV-1 activity.

Haro I, Gómara MJ, Galatola R, Domènech O, Prat J, Girona V, Busquets MA.

Biochim Biophys Acta. 2011 Jun;1808(6):1567-73. doi: 10.1016/j.bbamem.2011.02.019. Epub 2011 Mar 4.

48.

Antibodies against β-fibrin synthetic peptides: a study of their association with the immunogenetic background and disease course of rheumatoid arthritis patients.

Haro I, Gómara MJ, Pérez ML, Viñas O, Ercilla G, Gómez-Puerta JA, Sanmartí R.

Eur J Med Chem. 2011 Apr;46(4):1095-102. doi: 10.1016/j.ejmech.2011.01.024. Epub 2011 Jan 21.

PMID:
21295379
49.

Effect of synthetic peptides belonging to E2 envelope protein of GB virus C on human immunodeficiency virus type 1 infection.

Herrera E, Tenckhoff S, Gómara MJ, Galatola R, Bleda MJ, Gil C, Ercilla G, Gatell JM, Tillmann HL, Haro I.

J Med Chem. 2010 Aug 26;53(16):6054-63. doi: 10.1021/jm100452c.

PMID:
20718496
50.

A Langmuir monolayer study of the interaction of E1(145-162) hepatitis G virus peptide with phospholipid membranes.

Sánchez-Martín MJ, Haro I, Alsina MA, Busquets MA, Pujol M.

J Phys Chem B. 2010 Jan 14;114(1):448-56. doi: 10.1021/jp906900k.

PMID:
20000622

Supplemental Content

Support Center